Bibit pharmaceutical rushed to the scientific innovation board: annual revenue of 970000, loss of 137million, proposed to raise 2billion

RedI network Lei Jianping 7 month 2 Reported Wednesday

Guangzhou bebet Pharmaceutical Co., Ltd （ abbreviation ：“ Bebet medicine ”） The prospectus was submitted a few days ago , Ready to be listed on the science and technology innovation board .

Fund raising for the bebet pharmaceutical project 20 One hundred million yuan , among ,9.5 Billion yuan for new drug research and development projects ,5.55 Billion yuan is used for Qingyuan R & D center and preparation industrialization base construction project ,5 Billion yuan is used to supplement working capital .

Years of losses 1.37 Billion

Bebet medicine is a company oriented by clinical value 、 Biomedical enterprises focusing on independent research and development of innovative drugs . The company focuses on cancer 、 Autoimmune diseases 、 Metabolic diseases and other major diseases , Relying on the core technology platform built by independent research and development , The company continues to develop the world's first drug urgently needed in clinic （First-in-Class） And innovative drugs that do not meet clinical needs .

As of the date of this prospectus , The company's R & D pipeline has 6 The core products of innovative drugs independently developed have been in clinical trials or are about to start clinical trials .

among 2 Products have entered tailing microelectronics III Tailing microelectronics stage or key clinical trial stage ,1 Tailing microelectronics products are in tailing microelectronics II Tailing microelectronics phase clinical trial stage ,1 Tailing microelectronics products are in tailing microelectronics I Tailing microelectronics phase clinical trial stage ,1 Tailing microelectronics products have obtained clinical trial approval and are in tailing microelectronics I Tailing microelectronics phase I clinical trial is under preparation ,1 Tailing microelectronics products have been submitted to tailing microelectronics I Tailing microelectronics phase I clinical trial application .

The prospectus shows , Bebet 2019 year 、2020 year 、2021 The annual revenue is 35 Ten thousand yuan 、37.69 Ten thousand yuan 、97 Ten thousand yuan ; Net losses are 5893.75 Ten thousand yuan 、6126 Ten thousand yuan 、1.37 One hundred million yuan ; The net loss after deducting non-profit is 3064 Ten thousand yuan 、6489 Ten thousand yuan 、1.45 One hundred million yuan .

Qian Changgeng controls 44% equity

The actual controller of bebet medicine is Qian Changgeng , No controlling shareholder .

IPO front , Qian Changgeng directly owns the company 15.2840% Shares of , Is the company's largest shareholder , At the same time, he controls the company by serving as the executive partner of Guangzhou Pharmaceutical engine 8.5899% Shares of .

According to Qian Changgeng and Cai Xiong （ Direct holding companies 11.1364% Shares of ）、 Xiong Yan （ Direct holding companies 8.9479% Shares of ） Signed 《 A consensus agreement 》, The parties agree , In caixiong 、 Xiong Yan, as a shareholder of bebet, exercises the proposal right 、 The right to nominate 、 Or on the board 、 shareholders （ Big ） When shareholders' voting rights are exercised at the meeting , Caixiong 、 Xiong Yan exercises the relevant proposal right according to Qian Changgeng's opinion 、 Nomination and voting rights .

The agreement is valid until the date when the initial public offering of bebet pharmaceutical is approved and officially listed 36 Months .

Based on the above arrangement , Qian Changgeng totally controlled bebet medicine 43.9582% Shares of , And Qian Changgeng is the founder of bebet medicine , In the past two years, he has controlled more than half of the board seats of bebet pharmaceutical and served as the chairman of bebet pharmaceutical 、 The general manager . Accordingly , Qian Changgeng is the actual controller of bebet .

Besides , Wang Yanong holds shares 4.6532%, Wu Chun holds shares 4.4442%, Geping holds 3.7152%, Ruixiangyuan No. 1 holds 3.6381%;

Yuexiu phase II holds 2.9105%, Yingke Jiyun 、 PCCW value holds 2.603%, Chen Xiaoyuan's shareholding is 2.2498%, Liu Yi holds 2.2016%.

Qian Changgeng is the chairman 、 The general manager , Caixiong is a director of the company 、 Deputy general manager , Caixiong is an American citizen , Xiong Yan is the vice chairman of the company .

Bebet medicine is 2021 year 7 A round of financing was carried out in August , At that time, the pre investment valuation was 33 One hundred million yuan , The price per share is 30.1103 element .

IPO after , Qian Changgeng holds shares 12.2274%, Caixiong holds shares 8.9093%, Xiong Yan holds 7.1585%, Guangzhou Pharmaceutical engine holds 6.8721%, Wang Yanong holds 3.7227%, Wu Chun holds 3.5555%, Geping holds 2.9723%, Ruixiangyuan No. 1 holds 2.9105%.

———————————————

Lei Di was founded by Lei Jianping, a senior media person , If reproduced, please indicate the source .